Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GLMD | US
0.88
23.16%
Healthcare
Biotechnology
30/06/2024
21/10/2024
4.68
3.90
4.70
3.80
Galmed Pharmaceuticals Ltd. a biopharmaceutical company focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol an oral therapy which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition it engages in the development of Amilo-5MER a 5 amino acid synthetic peptide methionine threonine alanine aspartic acid and valine. It has a license agreement with Samil Pharma. Co. Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv Israel.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
140.3%1 month
149.1%3 months
609.2%6 months
436.3%-
-
0.44
-
-
0.32
-
-
-6.14M
7.05M
7.05M
-
-
-
-
-52.67
-
2.30
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.30
Range1M
7.79
Range3M
23.56
Rel. volume
1.00
Price X volume
1.76M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Alzamend Neuro Inc. Common Stock | ALZN | Biotechnology | 1.73 | 7.74M | 3.28% | n/a | 0.00% |
Moleculin Biotech Inc | MBRX | Biotechnology | 2.67 | 7.59M | 3.29% | n/a | 3.00% |
Pulmatrix Inc | PULM | Biotechnology | 2.04 | 7.45M | 0.97% | n/a | 0.18% |
Cyclerion Therapeutics Inc | CYCN | Biotechnology | 2.9099 | 7.32M | 16.40% | n/a | 0.00% |
Orgenesis Inc | ORGS | Biotechnology | 1.53 | 7.30M | -27.49% | n/a | -84.02% |
Virax Biolabs Group Limited Ordinary Shares | VRAX | Biotechnology | 1.63 | 7.08M | 6.54% | n/a | 4.18% |
Purple Biotech Ltd | PPBT | Biotechnology | 4.49 | 7.07M | 2.75% | n/a | 0.89% |
CDIO | CDIO | Biotechnology | 0.231 | 7.07M | 9.53% | n/a | 28.31% |
Vaccinex Inc - Ordinary Shares | VCNX | Biotechnology | 2.69 | 6.99M | 6.32% | n/a | -4.26% |
Aptose Biosciences Inc | APTO | Biotechnology | 0.3889 | 6.96M | 6.75% | n/a | -37.59% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.32 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 0.44 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 609.18 | 72.80 | Riskier |
Debt to Equity | - | -1.23 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 7.05M | 3.66B | Emerging |